[1] HAN R,YANG H,LI Y,et al.Valeric acid acts as a novel HDAC3 inhibitor against prostate cancer[J].Med Oncol,2022,39(12):213-223.
[2] PEI YUIN J L,JIA SHIN J T,JING C B,et al.Retrospective Analysis of Clinical Outcomes of Stereotactic Body Radiation Therapy for Localized Prostate Cancer at an Asian Cancer Specialist Centre[J].Asian Pac J Cancer Prev,2023,24(2):545-550.
[3] MARRA G,VALERIO M,HEIDEGGER I,et al.Management of patients with node-positive prostate cancer at radical prostatectomy and pelvic lymph node dissection:a systematic review[J].Eur Urol Oncol,2020,3(5):565-581.
[4] MESSING E M,MANOLA J,YAO J,et al.Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy[J].Lancet Oncol,2006,7(6):472-479.
[5] XIN Z,LI Y,MENG L,et al.Elevated expression of the MYB proto-oncogene like 2(MYBL2)-encoding gene as a prognostic and predictive biomarker in human cancers[J].Math Biosci Eng,2022,19(2):1825-1842.
[6] LI Q,WANG M,HU Y,et al.MYBL2 disrupts the Hippo-YAP pathway and confers castration resistance and metastatic potential in prostate cancer[J].Theranostics,2021,11(12):5794-5812.
[7] 赫捷,陈万青,李霓,等.中国前列腺癌筛查与早诊早治指南(2022,北京)[J].中国肿瘤,2022,31(1):1-30.
[8] YLITALO E B,THYSELL E,LANDFORS M,et al.A novel DNA methylation signature is associated with androgen receptor activity and patient prognosis in bone metastatic prostate cancer[J].Clin Epigenetics,2021,13(1):133-147.
[9] NABIAN N,GHALEHTAKI R,COUÑAGO F.Necessity of pelvic lymph node irradiation in patients with recurrent prostate cancer after radical prostatectomy in the PSMA PET/CT era:a narrative review[J].Biomedicines,2023,11(1):38-54.
[10] AKHOUNDOVA D,FENG F Y,PRITCHARD C C,et al.Molecular genetics of prostate cancer and role of genomic testing[J].Surg Pathol Clin,2022,15(4):617-628.
[11] OH I H,REDDY E P.The myb gene family in cell growth,differentiation and apoptosis[J].Oncogene,1999,18(19):3017-3033.
[12] CICIRÒ Y,SALA A.MYB oncoproteins:emerging players and potential therapeutic targets in human cancer[J].Oncogenesis,2021,10(2):19-33.
[13] LU S,WANG J,CHITSAZ F,et al.CDD/SPARCLE:the conserved domain database in 2020[J].Nucleic Acids Res,2020,48(D1):D265-D268.
[14] PAPETTI M,AUGENLICHT L H.MYBL2,a link between proliferation and differentiation in maturing colon epithelial cells[J].J Cell Physiol,2011,226(3):785-791.
[15] 杨明,朱旭东,沈炀,等.MYBL2在前列腺癌患者组织中高表达并与不良预后相关[J].南方医科大学学报,2022,42(8):1109-1118.
[16] LI X,JIAO M,HU J,et al.miR-30a inhibits androgen-independent growth of prostate cancer via targeting MYBL2,FOXD1,and SOX4[J].Prostate,2020,80(9):674-686.
[17] 许丁文,雒森,袁红网,等.基于生物信息学分析MYBL2在卵巢癌耐药性中的作用及其机制[J].中国现代应用药学,2020,37(10):1166-1170.
[18] LI J,CHEN H.Actin-binding Rho activating C-terminal like(ABRACL) transcriptionally regulated by MYB proto-oncogene like 2(MYBL2) promotes the proliferation,invasion,migration and epithelial-mesenchymal transition of breast cancer cells[J].Bioengineered,2022,13(4):9019-9031.
[19] LIU M,DU Q,MAO G,et al.MYB proto-oncogene like 2 promotes hepatocellular carcinoma growth and glycolysis via binding to the Optic atrophy 3 promoter and activating its expression[J].Bioengineered,2022,13(3):5344-5356.
[20] MAO X,ORCHARD G,LILLINGTON D M,et al.Amplification and overexpression of JUNB is associated with primary cutaneous T-cell lymphomas[J].Blood,2003,101(4):1513-1519.
[21] National Comprehensive Cancer Network.NCCN clinical practice guidelines in oncology:prostate cancer(version1.2022)[EB/OL].2021-09-10/2021-10-11.https://www.nccn.org/guidelines/category_1
[22] YOSHIKAWA Y,STOPSACK K H,WANG X V,et al.Increased MYBL2 expression in aggressive hormone-sensitive prostate cancer[J].Mol Oncol,2022,16(22):3994-4010. |